NasdaqGS:SRRKBiotechs
Scholar Rock’s Apitegromab FDA Progress Might Change The Case For Investing In SRRK
Scholar Rock Holding Corporation reported a US$102.22 million net loss for the third quarter ended September 30, 2025, with plans to resubmit the biologics license application for apitegromab following constructive discussions with the FDA.
This regulatory update highlights Scholar Rock's intention to accelerate the U.S. launch of apitegromab in 2026 by leveraging an additional fill-finish facility.
We’ll explore how Scholar Rock's positive momentum toward FDA approval for apitegromab could...